


Investor Presentation

Mid&Small Virtual 2023 June 2023

Strictly Private and Confidential

Shareholders' Structure & Key People



Key People





Umberto Perillo Chief Executive Officer

Mr. Perillo is the General Director and CEO of Svas Biosana Group since 2012. He joined the company in 1979, and has since dedicated himself to the growth and the strategic development of the group by optimizing its business model and by managing the most important recent acquisitions.

Andrea Efficace Mark Medical CEO & Group CFO

Mr. Efficace is CFO of Svasa Biosana Group since 2001, and CEO of Mark Medical since 2015. He joined the firm in 1998, and has since developed his professional career within the group. He's a certified chartered accountant and auditor.



Group Overview

Svas Biosana «At a Glance» Key Financial Highlights

Millions of Euro	2019A	2020A	2021A	2022A	
Net Revenues	73,6	76,0	81,1	97,2	
YoY A	<i>6,4%</i>	<i>3,4%</i>	<i>6,6</i> %	19,9%	
EBITDA	9,2	9,6	10,6	11,9	
EBITDA Margin	12,5%	12,6%	<i>13,1%</i>	<i>12,2%</i>	
EBIT	5,2	5,1	5,7	6,3	
EBIT Margin	7,0%	6,7%	7,1%	_{6,4%}	
Net Income	2,5	2,5	3,2	3,6	
Margin %	<i>3,4%</i>	3,3%	3,9%	<i>3,7%</i>	
NFP	37,5	36,9	17,0	21,7	
Equity	22,8	27,7	51,0	54,5	



FY 2022 consolidated Revenues include the revenue of Bormia d.o.o. (which was acquired in June 2022) of 2H 2022. Bormia d.o.o. 1H 2022 revenues, equal to €6.5m, are not included in FY 2022 consolidated revenues.

SVAS Biosana Group ("SVAS", the "Company" or the "Group") is an Italian leading player in the medical devices and disposables sector, acting both as a manufacturer and as a distributor.

The Group was founded in Southern Italy in 1972 by Francesco Fausto Perillo, with the aim to provide medical devices in the area. Today, the Group is headquartered in Somma Vesuviana (Naples - NA) with three production plants located in Ottaviano (NA) and Somma Vesuviana (NA).

Medical devices are the core of Svas Biosana commercial offer. The Group counts more than 16,000 references, both with own and third parties brands.


The Group consists of three main companies:

- Svas Biosana: production and distribution of incontinence aids, cotton wool and personal care products, procedural packs (socalled custom packs), dressings, surgical instruments, as well as numerous other medical devices. It constitutes of three business lines: (i) Svas; (ii) Farmex; and (iii) Medical;
- Mark Medical Group: acquired by Svas Biosana in December 2015. It distributes medical items and medical-health devices supplied by top world producers exclusively in the Balkan Area (Slovenia, Croatia, Serbia and Bosnia-Herzegovina). Mark Medical is present in each of these countries in a widespread manner with subsidiaries dedicated to distribution and local assistance.
- Bormia Group: acquired by Svas Biosana in June 2022. Bormia Group is active in the distribution of specialized medical devices for cardiac surgery, anaesthesiology, critical care, endovascular procedures and neuroradiology in Slovenia, Croatia, Serbia and Bosnia.



Market	Italian Market		Foreign Markets		
Business Line	FARMEX	MEDICAL	Svas	empowering healthcare.™	
Activity	Production and sale	Production and sale	Distribution and sale	Distribution and sale	Distribution and sale
Products	Products for incontinence	Custom packs	Medical devices	Medical devices	Medical devices
Activity	Production		Distribution		
				Svas Biosana Inv	estor Presentation


Geographical Presence and History Somma Vesuviana (NA) – 12.200 sqm: Chemical Chemical Division Chemical Chemical Division Chemical Chemical Division Chemical Division Chemical Division Chemical Chemical Division Chemical Chemical Division Chemical Chemical Chemical Division Chemical Chemical Division Division Chemical Division Chemical Division Division Chemical Division Division Chemical Division Chemical Division Chemical Division Division Chemical Division Chemical Division Division Chemical Division Division Chemical Division Chemical Division Division Chemical Ch



SVAS BIOSANA Source: Company management

Svas Biosana Investor Presentation June 2023

Warehouses and




Source: Company management.

Production – Main products

Farmex



Adult Incontinence Aids



Medical



Custom Pack



Standard Dressings



Cotton Wool



Advanced Dressings



Surgical Suction Systems



Infusion and Drainage Devices



Distribution – Main products

Specialties





Drug Transfer Devices



Peritoneal Dyalisis Products

Cardiac Surgery



Cardiopulmonary

Radiology & Imaging



Contrast Media

Critical Care



Catheters and Infusion Disposable Endotracheal Tubes Systems

Orthopedics and Arthroscopy





Orthopedic Implants

Arthroscopy Implants and Equipment

Cardiology





Guide Wires and Coronary Drug **Eluting Stent** Catheters

Robotics



Robotic Magnetic Navigation System

Svas Biosana Investor Presentation June 2023

7



Laparoscopic Instruments



Advanced Medications





SVAS BIOSANA

Infusion Lines



Surgical Instruments & Containers



Humidifiers

Devices












Group Overview FY 2022 Sales Breakdown





(1) FY 2022 Sales Breakdown are not audited. FY 2022 consolidated Revenues include the revenue of Bormia d.o.o. (which was acquired in June 2022) of 2H 2022. Bormia d.o.o. 1H 2022 revenues, equal to €6,5m, are not included in FY 2022 consolidated revenues. Svas Biosana Investor Presentation June 2023


8

Source: Company management.

Group Overview

Investment Highlights and Market Dynamics

1. Rich and consolidated portfolio of products to satisfy chronic, medical and surgical healthcare needs



2. Qualified commercial structure and close relationship with medical operators generate additional value while creating high entry barriers





Source: (1) Eurostat Statistics, May 2021

(2) Eutore life expectance in Europe taking into account the impact of smoking, obesity, and alcohol, Janseen et al. 2021

(2) Flate the expectation in Europe daming the decourter an impact of anothing, obcasity, and addition of an activity of the event o

Men


(4) Global preventive healthcare market \$ 287 billion by 2027, iHealthcareAnalyst, March 2021

(5) Piano Nazionale di Ripresa e Resilienza, April 2021

Svas Biosana Investor Presentation June 2023


Financial Data Key Financial Highlights


Millions of Euro	2018A	2019A	2020A	2021A	2022A
Net Revenue	69,1	73,6	76,0	81,1	97,2
YoY∆		6,4%	<i>3,4%</i>	<i>6,6%</i>	19,9%
EBITDA	8,3	9,2	9,6	10,6	11,9
EBITDA Margin	12,0%	12,5%	12,6%	<i>13,1%</i>	<i>12,2%</i>
EBIT	4,5	5,2	5,1	5,7	6,3
EBIT Margin	<i>6,5%</i>	7,0%	<i>6,7%</i>	7,1%	<i>6,4%</i>
Net Income	1,9	2,5	2,5	3,2	3,6
<i>Margin %</i>	<i>2,8%</i>	3,4%	3,3%	3,9%	<i>3,7%</i>
NFP	36,1	37,5	36,9	17,0	21,7
Equity	22,4	22,8	27,7	51,0	54,5
NFP /EBITDA	4,3x	4,1x	3,9x	1,6x	1,8x
NFP / Equity	1,6x	1,6x	1,3x	0,3x	0,4x





* FY 2022 consolidated Revenues include the revenue of Bormia d.o.o. (which was acquired in June 2022) of 2H 2022. Bormia d.o.o. 1H 2022 revenues, equal to €6,5m, are not included in FY 2022 consolidated revenues.







Update on M&A Transaction



In June 2022, Svas Biosana completed the acquisition of 75% of the capital of Bormia d.o.o. (the remaining 25% of shares are owned by the company itself). The group Bormia is active in the distribution of specialized medical devices in Slovenia, Croatia, Serbia and Bosnia. Through this acquisition, Svas Biosana consolidates its position in the medical device market in the Balkan area by increasing its size and commercial strength in the area.




Bormia Key Financial Highlights

Millions of Euro	2020A	2021A	Var%
Revenue	8,7	11,0	+26,4%
EBITDA	1,13	1,25	+11%
EBITDA Margin	13,0%	11,4%	
Net Income	0,8	0,9	+9,3%
NFP (cash)	(0,21)	(0,96)	



Annex Group Structure

(1) Update to June 16th,2023 Source: Group Management



12

June 2023

Annex Consolidated Income Statement

	31/12/2021	%	31/12/2022	%	Delta	%
Revenues from sales and services	81.085.102	100,0%	97.226.932	100,0%	16.141.830	19,9%
External costs	60.383.563	74,5%	74.943.464	77,1%	14.559.901	24,1%
Added Value	20.701.539	25,5%	22.283.468	22,9%	1.581.929	7,6%
Cost of labor	11.022.402	13,6%	12.675.540	13,0%	1.653.138	15,0%
Other revenues	967.679	1,2%	2.289.652	2,4%	1.321.973	136,6%
EBITDA	10.646.816	13,1%	11.897.580	12,2%	1.250.764	11,7%
Depreciations and Amortizations	4.875.669	6,0%	5.640.213	5,8%	764.544	15,7%
EBIT	5.771.147	7,1%	6.257.367	6,4%	486.220	8,4%
Interest expenses/incomes	(1.752.985)	-2,2%	(1.600.587)	-1,6%	152.398	-8,7%
EBT	4.018.162	5,0%	4.656.780	4,8%	638.618	15,9%
Revaluations & Write-Downs	0	0,0%	0	0,0%	0	0,0%
Pre-Tax Result	4.018.162	5,0%	4.656.780	4,8%	638.618	15,9%
Taxes	856.979	1,1%	1.085.305	1,1%	228.326	26,6%
Net Income	3.161.183	3,9%	3.571.475	3,7%	410.292	13,0%



Annex Consolidated Balance Sheet

	31/12/2021	31/12/2022	Delta
Net intangible fixed assets Net tangible fixed assets	10.749.503 25.639.396	11.023.670 26.209.159	274.167 569.763
Equity investments and other financial fixed assets	159.786	229.980	70.194
Fixed capital	36.548.685	37.462.809	914.124
Inventories Receivables from customers Other credits Prepayments and accrued income Short-term operating activities	25.126.150 31.827.089 4.316.886 743.824 62.013.949	29.821.907 38.995.140 5.473.375 878.560 75.168.982	4.695.757 7.168.051 1.156.489 134.736 13.155.033
Payables to suppliers Advances Tax and social security payables (within the following	23.336.838 72.468 2.214.454	28.198.447 104.610 2.498.942	4.861.609 32.142 284.488
year) Other debts Accrued liabilities and deferred income Short-term operating liabilities	1.489.860 1.196.077 28.309.697	2.070.471 1.408.220 34.280.690	580.611 212.143 5.970.993
Net working capital	33.704.252	40.888.292	7.184.040
Employee severance indemnity Tax and social security payables (beyond the following year) Other medium and long-term liabilities Medium and long-term liabilities	2.003.046 25.000 240.846 2.268.892	1.927.528 0 249.560 2.177.088	(75.518) (25.000) 8.714 (91.804)
Net Invested Capital	67.984.045	76.174.013	8.189.968
Equity Net Financial Debt	(50.965.741) (17.018.304)	(54.509.266) (21.664.747)	(3.543.525) (4.646.443)
Equity and Net Financial Debt	(67.984.045)	(76.174.013)	(8.189.968)



Legal Disclaimer

For the purposes of this disclaimer, this presentation (the "Presentation") comprises the attached slides and any materials distributed at, or in connection with, the Presentation has been prepared by Svas Biosana S.p.A. (the "Company") solely for information and discussion purposes in connection with the admission of its shares ("Shares") on AIM Italia/Mercato Alternativo del Capitale organized and managed by Borsa Italiana S.p.A. ("AIM Italia") and, therefore, it is preliminary in nature.

The information provided in this Presentation is being furnished to you solely for your information on a confidential basis and, as such, has not been prepared with a view to public disclosure. Neither this document nor any copy thereof may be retained by you or reproduced, redistributed or passed on, in whole or in part, directly or indirectly, to any other person. Therefore, you undertake vis-à vis the Company (i) to keep secret any information of whatever nature relating to the Company and its affiliates including the fact that the information has been provided ("Information"); (ii) not to disclose any Information to anyone; (iii) not to make or allow any public announcements or communications concerning the Information; and (iv) to use reasonable endeavours to ensure that Information are protected against unauthorized access.

This Presentation is not an advertisement and does not constitute an offer or invitation to purchase or subscribe for any Share and neither it or any part of it shall form the basis of or be relied upon in connection with any contract or commitment or investments decision whatsoever. The Company has not prepared and will not prepare any prospectus for the purpose of the initial public offering of the Shares on Euronext Growth Milan("Private Placement"). Any decision to purchase or subscribe for Shares in connection with the Private Placement should be made independently of this Presentation. This Presentation does not constitute a recommendation regarding the Shares to be offered in the Private Placement. Therefore, nothing in this Presentation shall create any binding obligation or liability on the Company and its affiliates and any of their advisors or representatives.

This Presentation has been prepared solely for the use in connection with the possible Private Placement of Shares by the Company and other selling shareholders. The information contained in this document has not been independently verified and no representation or warranty express or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained herein. None of the Company or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this Presentation or its contents or otherwise arising in connection with this Presentation.

THIS PRESENTATION IS ADDRESSED SOLELY TO ITALIAN QUALIFIED INVESTORS WITHIN THE MEANING OF ARTICLE 34-TER, PARAGRAPH 1, LETTER B), OF CONSOB REGULATION ON ISSUERS NO. 11971 OF MAY 14, 1999, AS SUBSEQUENTLY AMENDED AND TO CERTAIN OTHER PERSONS IN MEMBER STATES OF THE EUROPEAN ECONOMIC AREA ("EEA") OTHER THAN ITALY (IN RESPECT OF WHICH THE REGULATION AND REQUIREMENTS REFERRED TO ABOVE APPLY) WHO ARE "QUALIFIED INVESTORS" WITHIN THE MEANING OF ANNEX II, SECTION I, OF THE DIRECTIVE 2014/65/UE. THE PRIVATE PLACEMENT OF SHARES OF THE COMPANY, IF ANY, WILL BE MADE AS PART OF THE ADMISSION OF THE SHARES OF THE COMPANY ON EURONEXT GROWTH MILAN AND REPRESENTS A CONDITION OF SUCH ADMISSION TO TRADING. THIS DOCUMENT IS NOT ADDRESSED TO ANY MEMBER OF THE GENERAL PUBLIC NEITHER IN ITALY NOR ELSEWHERE. NO PUBLIC OFFERING OF SHARES IN ITALY OR ELSEWHERE WILL BE MADE.

The information contained in this Presentation is not for publication or distribution, directly or indirectly, in, nor does it constitute an offer to sell or a solicitation of offers to buy securities in the United States of America, Australia, Canada or Japan or any jurisdiction where such distribution is unlawful, (as such term is defined in Regulation S under the United States Securities Act of 1933, as amended ("Securities Act"). The distribution of this Presentation in other jurisdictions may be restricted by law. Persons into whose possession the content of this Presentation come should inform themselves about and observe any such restrictions. Any failure to comply with the restrictions set forth above may constitute a violation of applicable securities laws.

Neither this Presentation nor any copy of it may be taken or transmitted into the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly or indirectly in the United States or America, its territories or possessions, or distributed, directly or indirectly or indirectly or indirectly in the United States or America, its territories or possessions, or distributed, directly or indirectly or a solicitation of an offer to buy securities in the United States or any other jurisdiction. The Shares proposed to be offered or sold within the United States, absent registration requirements of the Securities Act and may not be offered or sold within the United States, absent registration requirements of the Securities in the United States.

Certain information contained in this Presentation may contain forward-looking statements which involve risks and uncertainties and are subject to change. In some cases, these forward-looking statements can be identified by the use of words such as "believe", "anticipate", "estimate", "target", "potential", "expect", "intend", "predict", "project", "could", "should", "may", "will", "plan", "aim", "seek" and similar expressions. The forecasts and forward-looking statements included in this document are necessarily based upon a number of assumptions and estimates that are inherently subject to significant business, operational, economic and competitive uncertainties and contingencies as well as assumptions with respect to future business decisions that are subject to change. By their nature, forward-looking statements involve known and unknown risks and uncertainties, because they relate to events, and depend on circumstances, that may or may not occur in the future. Furthermore, actual results may differ materially from those contained in any forward-looking statements speak only as at the date of this Presentation. The Company cautions you that forward looking-statements are not guarantees of future performance and that its actual financial position, business strategy, plans and objectives of management for future operations are consistent with the forward-looking statements contained in this Presentation, those results or developments may not be indicative of results or developments in future periods. The Company's expectations with regard thereto or any change in events, or developments in future periods. The Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

The information, views and opinions expressed in this Presentation are provided as of the date of this Presentation and remain subject to verification, completion and change without notice. Neither the Company and its affiliates, nor any of their advisors or representatives shall be obliged to furnish or to update any information or to notify or to correct any accuracies in any information.

You should not act or rely on, or make any use of the content of, this Presentation. This Presentation does not purport to be comprehensive. No representation or warranty, express or implied, is given by or on behalf of the Company or any of its directors, officers, advisers, agents or employees or any of their directors, officers, advisers, agents or employees thereof, or any other person as to the accuracy, truthfulness, fairness, materiality or completeness of the information or opinions contained in this Presentation. No liability whatsoever is accepted by the Company or any of its directors, officers, advisers, agents or employees thereof, nor any other person for any loss howsoever arising, directly, from any use of such information or opinions or otherwise arising in connection therewith. By accepting this Presentation you agree to be bound by the foregoing restrictions and you will treat as strictly private and confidential all such information and take all reasonable steps to preserve such confidentiality.

